Cargando…

Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC

BACKGROUND: To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans. METHODS: Twenty-six lung IMRT and 26 proton PSPT plans were included in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Giaddui, Tawfik, Chen, Wenzhou, Yu, Jialu, Lin, Liyong, Simone, Charles B., Yuan, Lulin, Gong, Yutao U. T., Wu, Q. Jackie, Mohan, Radhe, Zhang, Xiaodong, Bluett, Jaques B., Gillin, Michael, Moore, Kevin, O’Meara, Elizabeth, Presley, Jennifer, Bradley, Jeffrey D., Liao, Zhongxing, Galvin, James, Xiao, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855766/
https://www.ncbi.nlm.nih.gov/pubmed/27142674
http://dx.doi.org/10.1186/s13014-016-0640-8
_version_ 1782430409330524160
author Giaddui, Tawfik
Chen, Wenzhou
Yu, Jialu
Lin, Liyong
Simone, Charles B.
Yuan, Lulin
Gong, Yutao U. T.
Wu, Q. Jackie
Mohan, Radhe
Zhang, Xiaodong
Bluett, Jaques B.
Gillin, Michael
Moore, Kevin
O’Meara, Elizabeth
Presley, Jennifer
Bradley, Jeffrey D.
Liao, Zhongxing
Galvin, James
Xiao, Ying
author_facet Giaddui, Tawfik
Chen, Wenzhou
Yu, Jialu
Lin, Liyong
Simone, Charles B.
Yuan, Lulin
Gong, Yutao U. T.
Wu, Q. Jackie
Mohan, Radhe
Zhang, Xiaodong
Bluett, Jaques B.
Gillin, Michael
Moore, Kevin
O’Meara, Elizabeth
Presley, Jennifer
Bradley, Jeffrey D.
Liao, Zhongxing
Galvin, James
Xiao, Ying
author_sort Giaddui, Tawfik
collection PubMed
description BACKGROUND: To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans. METHODS: Twenty-six lung IMRT and 26 proton PSPT plans were included in the study. Dose Volume Histograms (DVHs) for targets and normal structures were analyzed. The quality of IMRT plans was assessed using a knowledge-based engineering tool. RESULTS: Most of the RTOG 1308 dosimetric criteria were achieved. The deviation unacceptable rates were less than 10 % for most criteria; however, a deviation unacceptable rate of more than 20 % was computed for the planning target volume minimum dose compliance criterion. Dose parameters for the target volume were very close for the IMRT and PSPT plans. However, the PSPT plans led to lower dose values for normal structures. The dose parameters in which PSPT plans resulted in lower values than IMRT plans were: lung V(5Gy) (%) (34.4 in PSPT and 47.2 in IMRT); maximum spinal cord dose (31.7 Gy in PSPT and 43.5 Gy in IMRT); heart V(5Gy) (%) (19 in PSPT and 47 in IMRT); heart V(30Gy) (%) (11 in PSPT and 19 in IMRT); heart V(45Gy) (%) (7.8 in PSPT and 12.1 in IMRT); heart V(50%) (Gy) (7.1 in PSPT and 9.8 in IMRT) and mean heart dose (7.7 Gy in PSPT and 14.9 Gy in IMRT). CONCLUSIONS: The revised RTOG 1308 dosimetric compliance criteria are feasible and achievable.
format Online
Article
Text
id pubmed-4855766
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48557662016-05-05 Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC Giaddui, Tawfik Chen, Wenzhou Yu, Jialu Lin, Liyong Simone, Charles B. Yuan, Lulin Gong, Yutao U. T. Wu, Q. Jackie Mohan, Radhe Zhang, Xiaodong Bluett, Jaques B. Gillin, Michael Moore, Kevin O’Meara, Elizabeth Presley, Jennifer Bradley, Jeffrey D. Liao, Zhongxing Galvin, James Xiao, Ying Radiat Oncol Research BACKGROUND: To establish the feasibility of the dosimetric compliance criteria of the RTOG 1308 trial through testing against Intensity Modulation Radiation Therapy (IMRT) and Passive Scattering Proton Therapy (PSPT) plans. METHODS: Twenty-six lung IMRT and 26 proton PSPT plans were included in the study. Dose Volume Histograms (DVHs) for targets and normal structures were analyzed. The quality of IMRT plans was assessed using a knowledge-based engineering tool. RESULTS: Most of the RTOG 1308 dosimetric criteria were achieved. The deviation unacceptable rates were less than 10 % for most criteria; however, a deviation unacceptable rate of more than 20 % was computed for the planning target volume minimum dose compliance criterion. Dose parameters for the target volume were very close for the IMRT and PSPT plans. However, the PSPT plans led to lower dose values for normal structures. The dose parameters in which PSPT plans resulted in lower values than IMRT plans were: lung V(5Gy) (%) (34.4 in PSPT and 47.2 in IMRT); maximum spinal cord dose (31.7 Gy in PSPT and 43.5 Gy in IMRT); heart V(5Gy) (%) (19 in PSPT and 47 in IMRT); heart V(30Gy) (%) (11 in PSPT and 19 in IMRT); heart V(45Gy) (%) (7.8 in PSPT and 12.1 in IMRT); heart V(50%) (Gy) (7.1 in PSPT and 9.8 in IMRT) and mean heart dose (7.7 Gy in PSPT and 14.9 Gy in IMRT). CONCLUSIONS: The revised RTOG 1308 dosimetric compliance criteria are feasible and achievable. BioMed Central 2016-05-04 /pmc/articles/PMC4855766/ /pubmed/27142674 http://dx.doi.org/10.1186/s13014-016-0640-8 Text en © Giaddui et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Giaddui, Tawfik
Chen, Wenzhou
Yu, Jialu
Lin, Liyong
Simone, Charles B.
Yuan, Lulin
Gong, Yutao U. T.
Wu, Q. Jackie
Mohan, Radhe
Zhang, Xiaodong
Bluett, Jaques B.
Gillin, Michael
Moore, Kevin
O’Meara, Elizabeth
Presley, Jennifer
Bradley, Jeffrey D.
Liao, Zhongxing
Galvin, James
Xiao, Ying
Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC
title Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC
title_full Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC
title_fullStr Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC
title_full_unstemmed Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC
title_short Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC
title_sort establishing the feasibility of the dosimetric compliance criteria of rtog 1308: phase iii randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage ii-iiib nsclc
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855766/
https://www.ncbi.nlm.nih.gov/pubmed/27142674
http://dx.doi.org/10.1186/s13014-016-0640-8
work_keys_str_mv AT giadduitawfik establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT chenwenzhou establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT yujialu establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT linliyong establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT simonecharlesb establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT yuanlulin establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT gongyutaout establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT wuqjackie establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT mohanradhe establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT zhangxiaodong establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT bluettjaquesb establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT gillinmichael establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT moorekevin establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT omearaelizabeth establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT presleyjennifer establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT bradleyjeffreyd establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT liaozhongxing establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT galvinjames establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc
AT xiaoying establishingthefeasibilityofthedosimetriccompliancecriteriaofrtog1308phaseiiirandomizedtrialcomparingoverallsurvivalafterphotonversusprotonradiochemotherapyforinoperablestageiiiiibnsclc